V-01-351

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameV-01-351

Drug Alias Namerecombinant fusion protein bivalent vaccine (Livzon Pharmaceutical)recombinant fusion protein bivalent vaccine (Livzon Pharmaceutical)V-01-351

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesLivzon Pharmaceutical Group Inc

China Registration ClassN/A

Develop Information

Active CompaniesLivzon Pharmaceutical Group Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A